ClinicalTrials.gg
Status unknownNCT03781557Updated Dec 20, 2018

Effects of Omega-3 Fatty Acids Supplement in Cognition of Young Healthy Adults and in Their Reaction Time of Computerized Test After 3 Months of Taking High-concentrated DHA and EPA Fish Softgels

A Phase 4 interventional study of Docosahexaenoic acid and Eicosapentaenoic acid in Cognition, Brain and Neuroscience, sponsored by Sulaiman AlRajhi Colleges. Status unknown. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-20.

Sponsored by Sulaiman AlRajhi Colleges · Phase 4, Interventional, and Other

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

In this trial, the investigators are going to investigate the improvement of cognitive brain domains after ingestion of omega 3 products that have high concentrations of DHA, Docosahexaenoic acid, and EPA, Eicosapentaenoic acid, in comparison to control group young healthy adults. The study will assess the improvement by computerized testing by their reaction time before and after the intervention. The researchers will follow the scientific and ethical regulations prevent any harmful effect on recruited subjects.

Read the detailed description

Research Question :

Research question: Will daily consumption of omega-3 fish oil improve brain cognitive domains?

Study Methodology Research Design:

A placebo-controlled, double-blinded, 3-armed randomized controlled trial.

Population and Sample :

Our target population will be young, healthy adults, educated academic students which are the students of Sulaiman Alrajhi Colleges in Kingdom of Saudi Arabia.

Regarding the sample size, the investigators will put into consideration the confidence level of 95%. Also, the investigators will take into account the size of our population which is the number of students in Sulaiman Al-Rajhi Colleges. In addition to that, the investigators will consider the margin of error to be around 10%. Taking these variables together will give us an estimated sample size of about 66 students which the investigators will reduce to 60 due to financial limitations.

Sampling strategy:

The investigators will recruit the participants from the students of Suliman Alrajhi Colleges by announcing through the emails and by spreading paper announcements in the campus and the housing for volunteering in the research as subjects and the investigators will try to give the participants activity points after coordinating with the students' affairs department. If more than 60 students volunteered for the trial, then the investigators will choose 60 of them based on the exclusion and inclusion criteria and by random sequence generation.

Plan of subjects' recruitment:

The investigators will recruit our subjects from the students of Suliman Al-Rajhi Colleges, both males and females sectors. The sample size will be 60 students in 3 arms (20 control, 20 high doses of Docosahexaenoic acid, DHA, and 20 high doses of Eicosapentaenoic acid, EPA,). The investigators will take the baseline characteristics and do the preliminary cognitive testing using Psytest, (TAP 2.3.1) software. Recruiting the subjects will be according to the exclusion and inclusion criteria mentioned below. After collecting the sample, the investigators will enroll the subjects in the study 6 students a day. So that the investigators will do the preliminary testing and take the baseline characteristics for 6 students at day 1 and then the day after the same group will start taking the intervention (either high dose DHA or high dose EPA or placebo) and another 6 students will be enrolled and so on. Hence day 10 will be the last day of enrollment and the process of enrollment will take 10 days. So, the investigators are going to have ten groups of subjects allocated randomly to the three arms of the study. After 90 days from the date of the enrollment, each group will be assessed, and the post-intervention testing will be carried out. The investigators will take the informed consent from all participant after explaining everything about the study and the potential side effects of supplements, in addition, to take their written agreement after explaining all their inquiries about the study.

Plan of data collectors' recruitment:

The investigators need the data collectors to help to keep an updated information on the subjects and assisting in the process of distributing the pills and their regular intake and also they will ensure quick communication. The investigators will need ten data collectors so that each data collector will supervise a group of six subjects, and these six students will be randomly assigned as mentioned before.

Randomization:

The investigators will do Block randomization in order to have equal numbers in the three arms of the study. Computer-generated random allocation sequences will be used, www.randomizer.org, and when carried out the randomization will help us avoiding selection bias so that no systematic differences exist. Then, the investigators will distribute the subjects in the three arms of the study randomly.

Blinding:

The investigators will make sure that the soft-gels of the DHA group, EPA group, and placebo group will look the same and taste the same so that blinding is not broken and allocation concealment is ensured. The investigators will also try to make the study double blinded.

Supplements and placebo groups:

The investigators will divide randomly the participants to three main groups who will take two softgels of different supplements which are:

  1. EPA-high-concentrated fish oil softgels that will provide 1374 mg of EPA and 500 DHA fatty acids per day out of 2500 mg total fat. The chosen product for this concentration is :

    , Sports Research, Omega-3 Fish Oil, Triple Strength, 1250 mg, 180 Softgels,

  2. DHA-high-concentrated fish oil softgels that will provide 1400 mg of DHA fatty acids per day out of 2000 mg of total fat. The chosen product for this concentration is :

    , DHA 700 Fish Oil,

  3. Olive oil softgels as a placebo that will be totally 2500 mg of fat The chosen product for this is :

    • Healthy Origin, Extra Virgin Olive Oil softgels,

The softgels will be taken every day by oral administration for 60 days and the participants will be instructed and followed by the investigators to take them after the meal and roughly in the same time to unify any possible factor during taking it. The investigators suggest taking it after launch meal immediately. The supplements will be stored in a healthy, cold, and safe environment to guarantee the bioavailability of the products.

The investigators will try to ensure that all supplements capsules have the same out-shape characteristics like color, shape, and size to enhance the double blinding that the investigators put in our research criteria. In addition, the investigators will bring uniformed containers to store the soft-gels and distribute the soft-gels among them to maintain blinding for researchers. That will be the same during distributing the capsules to the participants and it will be in a good-saving uniformed container.

Safety:

Many supplements of omega-3 are US FDA and Saudi FDA approved and can be found in the approved drugs list of each organization). According to the European Food Safety Authority in 2012 , long-term consumption of EPA and DHA supplements at combined doses of up to about 5 g/day, or EPA alone up to 1.8 g/day appear to be safe for the adult population and does not increase the risk of spontaneous bleeding episodes, or affect glucose homeostasis, immune function or lipid peroxidation.

Data collection and communication:

The investigators will distribute a limited amount of softgels every week and check for taking softgels.

Criteria for stopping follow-up and intervention in the subject:

Allergic reaction or exacerbated side effects that cannot be afforded Failure to daily follow-up and compliance to take the supplementation

Medication use :

Autoimmune disease Significant changes in lifestyle throughout the supplementation interval Including a 6.8 kg weight loss

Analysis:

The investigators will analyze the data using the SPSS software program. Descriptive analysis and statistical Drop-outs from the study will be excluded from the analysis, so the analysis type will be, per protocol analysis.

02

Conditions studied

  • Cognition
  • Brain
  • Neuroscience

Keywords

  • Omega-3
  • DHA fatty acids
  • EPA fatty acids
  • Cognition
  • Brain
  • Healthy Adult
  • Fish Oil
  • Human
03

In context

Lead sponsor

Sulaiman AlRajhi Colleges is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy
  • Young Adult (18-25)

Exclusion criteria

Exclusion Criteria:

  • Diet rich in fish oil: subjects should not use a diet rich in omega 3 poly-unsaturated fatty acids, that is defined as more than one portion a week or more than 4 portions a month of the following food items
  • Salmon Sardines • Flaxseed oil or whole flaxseed Illicit drug use

    • Medications of mental illnesses or that affect brain functions
  • Fish Allergy
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High-concentrated DHA

    High-concentrated DHA fish oil softgels

    Dietary Supplement: Docosahexaenoic acid

  • Experimental
    High-concentrated EPA

    High-concentrated EPA fish oil softgels

    Dietary Supplement: Eicosapentaenoic acid

  • Placebo comparator
    Olive Oil

    Olive Oil softgels

    Dietary Supplement: Olive oil

Interventions

  • Dietary supplementDocosahexaenoic acid

    High-concentrated DHA

    Also known as: MadreLabs, DHA 700 Fish Oil

  • Dietary supplementEicosapentaenoic acid

    High-concentrated EPA

    Also known as: Sports Research, Omega-3 Fish Oil, Triple Strength

  • Dietary supplementOlive oil

    Olive Oil softgels

06

What researchers measure

Primary outcomes

  1. Attention

    it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds

    Time frame: 5 minutes

  2. Working memory

    Working memory can be looked at as a system that keeps the information essential for solving difficult dilemmas and processing multi-level tasks or aspects of a situation in order to bring about a final impression. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.

    Time frame: 5 minutes

  3. Sustained attention

    it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.

    Time frame: 15 minutes

  4. stimulus-reaction incompatibility (Simon effect)

    Incompatibility occurs in a conflict situation in which divergent stimulus information has to be processed in parallel, thus triggering different reaction tendencies. The Simon and the Stroop effects (in the Colour-Word Interference Test) are classic examples of this effect. The present procedure tests the interference tendency in terms of stimulus-reaction incompatibility (Simon effect) . For this test, arrows that are directed to the left or the right are presented on the left or the right of a fixation point. Depending on the direction of the arrow, the test person should respond with the right or left hand irrespective of the side on which the arrow is presented.

    Time frame: 3 minutes

  5. Go/ No go

    this test will measure the specific ability of the subject to suppress an inappropriate response and to react only on the appearance of some stimuli and not in the presence of others, which requires significant central intervention. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.

    Time frame: 5 minutes

  6. Divided attention

    In this test, an auditory and a visual task must be taken simultaneously, to measure the subject's ability to carry out more than one task at the same time. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.

    Time frame: 10 minutes

  7. Alertness

    In this test, we will measure the reaction time. Simple reaction time measurements will be done, in which a diamond appears on the screen at random intervals and to which the subject should respond as quickly as possible by pressing a button. it will be measured by Psytest (TAP 2.3.1) computerised test to assess the reaction time related to it by milliseconds.

    Time frame: 5 minutes

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2019; primary completion for Apr 2019, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2018
First posted
Dec 20, 2018
StartEst.
Jan 1, 2019
Primary completionEst.
Apr 1, 2019
CompletionEst.
May 29, 2019
Last update
Dec 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03781557
Lead sponsor
Sulaiman AlRajhi Colleges
Responsible party
Sponsor
First posted
Dec 20, 2018
Start date
Jan 1, 2019 (estimated)
Primary completion
Apr 1, 2019 (estimated)
Completion
May 29, 2019 (estimated)
Last update
Dec 20, 2018

Study contacts

WESAM ALKASSAS, MBBS
Contact
13110021@srcolleges.org
+966538975400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docosahexaenoic Acids · Eicosapentaenoic Acid

Start the discussion